TIDMSBTX

RNS Number : 2069U

SkinBioTherapeutics PLC

22 November 2023

22 November 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Update regarding Nominated Adviser and Broker

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that, following the completion of the all-share merger between Cavendish Securities plc (previously named Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap Group plc), and as a consequence of internal reorganisation within the Cavendish Group, the Company has changed its Nominated Adviser and Broker from Cavendish Securities plc to Cavendish Capital Markets Limited.

For more information please contact:

 
 SkinBioTherapeutics plc                                       Tel: +44 (0) 191 495 
  Stuart J. Ashman, CEO                                                        7325 
  Manprit Randhawa, CFO 
 Cavendish Capital Markets Limited                             Tel: +44 (0) 20 7220 
  (Nominated Adviser & Broker)                                                 0500 
  Giles Balleny, Dan Hodkinson (Corporate 
  Finance) 
  Charlie Combe (Broking) 
  Dale Bellis, Tamar Cranford-Smith (Sales) 
 Instinctif Partners (financial press)                         Tel: +44 (0) 20 7457 
  Melanie Toyne-Sewell / Adam Loudon /                                         2020 
  Jack Kincade                                  SkinBioT herapeutics@instinctif.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps(TM), a food supplement to address the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:

www.skinbiotherapeutics.com   and www.axisbiotix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPFFFELLILLFIV

(END) Dow Jones Newswires

November 22, 2023 02:00 ET (07:00 GMT)

Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Skinbiotherapeutics Charts.
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Skinbiotherapeutics Charts.